Tata Medical and Diagnostics (TataMD), the new healthcare venture from the house of Tata, announced today that it has entered into a wide-ranging clinical collaboration with Chennai- based Anderson Diagnostics &Labs (ADL), to standardize the indigenously – developed TataMD CHECK in a bid to slow down the rate of new infections.
The collaboration with clinical experts of ADL has helped ensure that the “Made-in-India” TataMD CHECK diagnostic kit can be scaled rapidly with ADL having already successfully conducted over 10,000 COVID tests using this new, DGCA approved ICMR guidelines, novel diagnostic solution based on Feluda CRISPR Platform.
“Tata’s CRISPR-based platform is a rock-solid COVID test that can be programmed for early detection and treatment of a number of other diseases and conditions as well.
Theindigenously-developed TataMD CHECK based on Feluda offers a clear, quicker and more accessible alternative to RT-PCR, the current mainstay of COVID tests.
Our clinical partnership with Tata MD will help support the transformation of COVID testing to arrest the emergence of a second wave in India and around the world.” said Dr Srinivasaraman, Director, Anderson Diagnostics and Labs.